<DOC>
	<DOCNO>NCT01012167</DOCNO>
	<brief_summary>The project design address follow two primary aim : 1 . To determine whether adjunctive oxytocin superior placebo treatment persistent negative symptom , measure SANS total score , people schizophrenia . 2 . To determine whether adjunctive Galantamine superior placebo treatment cognitive impairment , measure improvement composite neurocognitive score people schizophrenia . The investigator also address follow secondary aim : 1 . To determine whether people schizophrenia treat adjunctive oxytocin , compare placebo , show great improvement marker negative symptom liability include : social affiliation , facial affect recognition , olfactory discrimination , initiation smooth pursuit latency internally-driven saccade . 2 . To determine whether people schizophrenia treat adjunctive Galantamine , compare placebo , show great improvement marker cognitive impairment liability include : predictive pursuit , P50 sensory gate visual-spatial working memory . The investigator address follow exploratory aim : 1 . To determine whether change marker negative symptom liability correlate change SANS total score . 2 . To determine whether change marker cognitive impairment liability correlate change composite neurocognitive score . 3 . To determine response oxytocin cognition domain assess MATRICS battery , determine response Galantamine cognition domain assess MATRICS , include primary neurocognitive outcome score . 4 . To determine whether differential response oxytocin Galantamine SANS total score , composite neurocognitive score , phenotypic measure negative symptom cognitive impairment liability . 5 . To determine whether oxytocin Galantamine associate : - adverse effect positive depressive symptom ; - adverse effect motor symptom ; - adverse effect laboratory EKG measure ; - increase occurrence side effect ; - social interest independent sexual desire .</brief_summary>
	<brief_title>Oxytocin Galantamine Versus Placebo Treatment Negative Symptoms Cognitive Impairments Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Any race Subjects meet DSMIV criterion schizophrenia schizoaffective disorder Judged clinically stable exceed threshold level positive , depressive , and/or extrapyramidal symptoms The minimum level negative symptom define follow : Scale Assessment Negative Symptoms ( SANS ) total score ( minus global item , inappropriate affect , poverty content speech attentional item ) 20 great ; OR SANS alogia global item score 3 great The maximum level psychotic , depressive , extrapyramidal symptom begin end leading : Brief Psychiatric Rating Scale ( BPRS ) psychotic factor score ( 4items ) less equal 16 BPRS Anxiety/Depression factor score ( 4items ) less equal 14 SimpsonAngusScale ( SAS ) total score ( 13items ) less equal 10 Subjects require antipsychotic ( ) two month dose last month Participants organic brain disorder ; mental retardation ; medical condition , whose pathology treatment could alter presentation treatment schizophrenia significantly increase risk associate propose treatment protocol Participants intermittent alcohol substance use exclude unless meet DSMIV criterion alcohol substance abuse ( nicotine ) within last month . Participants may treat one antipsychotic , except chlorpromazine , thioridazine , mesoridazine . These latter antipsychotic exclude concern anticholinergic property may interfere accurate assessment galantamine efficacy . Participants may treat anticholinergic medication clinically significant extrapyramidal symptom . Additionally , subject treat glycopyrrolate accept . Female participant may pregnant Female subject may take olanzapine dos high 30 mg . Male subject may take olanzapine dos high 40 mg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Schizophrenia , oxytocin , galantamine</keyword>
</DOC>